期刊文献+

液相色谱-串联质谱测定尿液中奥普力农的浓度 被引量:2

Determination of Olprinone in Urine by HPLC-MS-MS Assay
下载PDF
导出
摘要 目的建立尿液中奥普力农浓度的测定方法。方法采用LC-MS/MS法,以Agilent ZORBAX Eclipse Plus C1(84.6mm×150mm,5μm)为色谱柱;柱温:40℃;流动相为乙腈-40mmol/L甲酸铵(含0.04%甲酸)(体积比80∶20),流速:0.8ml/min,奥普力农尿样品经流动相稀释。样品经电喷雾离子源正离子化后,通过三重四级杆串联质谱仪,采用选择性反应监测对奥普力农(m/z251.0→155.0)和内标米力农(m/z212.1→140.0)进行测定。结果奥普力农在25~2000μg/L范围呈良好的线性关系,r=0.999(n=7),定量限浓度为25μg/L,相对回收率均>84.28%,日内RSD小于15%,色谱峰保留时间为1.746min。结论方法灵敏、准确、快速、特异性强,适用于奥普力农药动学研究。 Objective To establish an LC-MS/MS method for the determination of the olprinone content in the urine. Methods An LC-MS/MS method was adopted. Olprinone in urine was diluted with mobile phase and analyzed on a Agilent ZORBAX Eclipse Plus C18 [4.6 mm×150 mm, 5 um)column. The mobile phase was consisted of acetonitrile and 40 mmol/L of ammonium formate (including 0.04% formic acid) (80:20) with the flow rate of 0.8 ml/min and the column temperature of 40%. An Agilent 6410 triple quadrupole mass spectrometer system equipped with an electrospray ionization ion-trap source was used as the detector. The system was operated in the selected reaction monitoring mode transmitting m/z 251.0→155.0 transitions for both the olprinone and the internal standard. Results There was a good linearity over the concentration range of 25-2000 ug/L (r= 0.999, n=7). The quantization limit of this method was 25 ug/L, and the relative recovery was more than 84.28%. The intra-day precision was less than 15%, and the chromatographic peak tR was 1.746 min. Conclusion The method is sensitive, accurate, rapid, and suitable for the determination of olprinone in human urine.
出处 《今日药学》 CAS 2008年第3期24-25,共2页 Pharmacy Today
关键词 液相色谱-质谱法 奥普力农 尿药浓度 liquid chromatography-tandem mass spectrometry olprinone urine concentration
  • 相关文献

参考文献2

二级参考文献11

  • 1徐淑云.中华临床药物学[M].北京:人民卫生出版社,2003.594.
  • 2ALBRECHT C A, GIESLER G M, KAR B, et al.Intravenous milrinone infusion improves congestive heart failure caused by diastolic dysfunction: a briefcase series[J].Tex Heart Inst J, 2005, 32 (2): 220-223.
  • 3FELKER G M, BENZA R L, CHANDLER A B, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study [J].J Am Coll Cardiol, 2003, 41 (6) : 997-1003.
  • 4BAYRAM M, DE LUCA L, MASSIE M B, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes[J].Am J Cardiol, 2005, 96 (6A): 47G-58G.
  • 5SONODA K, IKEDA S, MIYAHARA Y, et al. Successful treatment of chronic pulmonary thromboembolism by long-term intermittent administration of milrinone, a phosphodiesterase inhibitor[J].Intern Med, 2002.41 (11): 961-966.
  • 6LOWES B D, TSVETKOVA T, EICHHORN E J, et al . Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol[J]. Int J Carcliol, 2001, 81 (2-3) : 141-149.
  • 7ARANDA J M, SCHOFIELD R S, PAULY D F. et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial [J ]. Am Heart J.2003, 145 (2): 324-329.
  • 8CHANANI N K, COWAN D B, TAKEUCHI K, et al. Milrinone facilitates resuscitation from cardiac arrest and attenuates postresuscltation myocardial dysfunction [J].Circulation, 2003. 108 (24): 3031-3035.
  • 9李为民,李悦,徐岩松,吴铭,孙薇.磷酸二酯酶抑制剂(米力农)对左室功能和机械效率影响的研究[J].黑龙江医学,2001,25(1):1-2. 被引量:6
  • 10严晓伟,邓华,林沁,焦镇,游凯.米力农单次静脉注射在重度心力衰竭患者的药代动力学[J].中国临床药理学杂志,2001,17(1):15-18. 被引量:5

共引文献47

同被引文献6

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部